NEW YORK (AFX) - Sinovac Biotech Ltd., a biotechnology firm based in Beijing, reported 'encouraging' preliminary results from an early-stage clinical test of a bird flu vaccine under development.
Early results of Sinovac's inactivated pandemic influenza vaccine, or Panflu, in Phase I clinical trials showed good immunogenicity with a seropositive rate of 78.3 percent, above the criteria for assessment of vaccines set by the European Union's Committee for Proprietary Medicinal Products.
The study enrolled 120 volunteers.
Sinovac said it will start the application process to start mid-stage, or Phase II, clinical trials. The company will submit its summary report of the Phase I clinical trial, plan and protocol for Phase II Clinical trial and other relevant documents, it said.
Sinovac shares edged up 3 cents to $2.73 on the American Stock Exchange.
Copyright 2006 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
© 2006 AFX News
